Why Alder thinks its late-comer migraine drug can succeed

Yet, with three competitors already on the market, carving out a niche will be a tall task for the Washington state-based biotech.

By Andrew Dunn • April 11, 2019

Sanofi expands insulin savings program, but affordability still an issue

Starting in June, the program will offer up to 10 boxes of pens, insulin vials or a combination of the two for $99 per month for certain patients. 

By Jacob Bell • April 10, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Indivior draws criminal indictment for opioid marketing practices

The federal government is seeking a $3 billion judgment and forfeiture of all assets, raising concerns about whether the company can survive.

By Jonathan Gardner • April 10, 2019

Time to test GSK's 2-drug HIV theory

With the highly anticipated approval of Dovato, GSK will soon get to see how many HIV patients gravitate to treatment regimens with fewer drugs.

By Jacob Bell • April 9, 2019

Coherus' Neulasta biosimilar surprises with strong early uptake

Shares in Coherus rose by as much as 25% after preliminary sales numbers for Udenyca came in seven times higher than what Wall Street had expected. 

By Ned Pagliarulo • April 8, 2019

340B hospital program leads to higher costs, PhRMA says

The research is the latest skirmish in a battle over the program, which health systems argue helps hospitals access affordable prescription drugs.

By Les Masterson • April 8, 2019

What to look for after Zolgensma's launch

An ICER report provides clues on how payers will hedge their reimbursement bets for a likely million-dollar neuromuscular-disease treatment.

By Jonathan Gardner • April 4, 2019

AARP report offers window into generic drugmaker pain

Retail prices for knock-off medicines fell 9.3% in 2017, the group found. While good for patients, continued declines have put generic drugmakers in a bind.

By Ned Pagliarulo • April 4, 2019

Purdue searched for new advertising agency: report

AdWeek says it obtained an email from Purdue's procurement department that details how the pharma was looking for a DTC advertising agency to promote a new product.

By Jacob Bell • April 3, 2019

Cigna, Express Scripts pledge to cap out-of-pocket insulin costs

Insulin makers and PBMs have faced rising pressure amid outrage over the cost of insulin, a lifesaving drug that's become a flashpoint for pricing concerns.

By Samantha Liss • April 3, 2019

German Merck finally gets yes for MS drug Mavenclad

The FDA approved the drug under a comparatively restrictive label, however, likely meaning the market opportunity for German Merck is small. 

By Suzanne Elvidge • April 2, 2019

Bluebird gene therapy on cusp of European market entry

A nod from an EMA expert panel means Bluebird's LentiGlobin for beta-thalassemia has just one last hurdle before it's cleared.

By Jacob Bell • March 29, 2019

Diabetes group nods to Vascepa, sending Amarin stock higher

The ADA updated its medical care standards to include Vascepa as Amarin works toward an expanded heart label for the drug.

By Andrew Dunn • Updated April 3, 2019

Louisiana selects Gilead for subscription-based hep C program

Gilead beat out AbbVie and Merck to be the provider of the first-of-its-kind payment model, which focuses on prisoners and Medicaid patients.

By Andrew Dunn • March 27, 2019

Lilly reveals Humalog pricing details amid larger scrutiny over insulin costs

The average list price on the widely used insulin rose more than 50% from 2014 to 2018, though Lilly noted the drug's average net price declined 8%.

By Jacob Bell • March 25, 2019

Specialty drug costs skyrocketed to $33B in Medicare Part D in 2015

Brand-name specialty drugs accounted for only 1% of all prescriptions in both Medicare Part D and Medicaid, but accounted for 30% of net spending.

By Rebecca Pifer • March 21, 2019

Sage's postpartum depression drug is approved. Now comes the hard part

Zulresso's label requires women to undergo a 60-hour infusion and only in certain settings, factors that may hamper the drug commercially.

By Jacob Bell • Updated March 20, 2019

Gilead raises prices on top-selling HIV treatments

The biotech hiked prices on more than a dozen products, including six HIV medicines that each surpassed $1 billion in 2018 sales.

By Andrew Dunn • March 19, 2019

Gearing up for growth

Launch decisions have a lasting impact. Here’s how short-term focus leads to long term success.

March 18, 2019

Aerie's eye drops win FDA approval

Branded as Rocklatan, the drops share an active ingredient with another intraocular pressure drug called Rhopressa that Aerie launched last year.

By Kristin Jensen • March 13, 2019

Dupixent label expansion opens door to thousands more patients

A new approval in younger atopic dermatitis patients could increase the list of people eligible to use the immunology drug by 200,000, according to Sanofi.

By Jacob Bell • March 12, 2019

Pharmas, PBMs and payers all take a slice along drug supply chain, Pew finds

As debate over drug pricing continues, Pew's report seeks to document the share each player pockets as medicines move through the system.

By Les Masterson • March 11, 2019

Mylan's Advair generic pressures GSK with strong launch

Priced at a 70% discount, Mylan's copy of the blockbuster respiratory drug has quickly captured market share.

By Ned Pagliarulo • March 8, 2019

AMAG pregnancy drug's future in doubt after key study miss

A confirmatory trial designed to support Makena's approval failed, likely crimping its commercial prospects. Yet the drug may still remain on market. 

By Jacob Bell • March 8, 2019

Lilly follows Gilead, Mylan lead with authorized generic play

A strategy to "cannibalize your own products before your competition does" — as one consultant put it — serves several purposes for drugmakers under pressure on price.

By Andrew Dunn • March 5, 2019